Genus PLC
8 March 2001
GENUS PLC ('GENUS')
FURTHER RE TRADING UPDATE
In response to the current outbreak of foot and mouth disease and the effect
this has had on Genus' operations, as identified in the company's previous
announcement of 1 March 2001, the board of Genus has taken the following
steps:
* 714 staff in the UK agricultural sections of the Breeding and Consulting
divisions and the head office staff have been put on short time working
hours or reduced salary to reduce staff costs by 20%
* All executive directors have taken a 20% cut in base salary
* All non-executive directors have waived their fees for March
These steps have been put into effect for the month of March. The board will
continue to review the situation as more information on the outbreak becomes
available, and is committed to protecting shareholder value in these extremely
difficult conditions.
Contact:
Richard Wood Genus plc Tel: 01270 536 501
Giles Elliott Bridgewell Corporate Finance Tel: 020 7523 5803
Charles Ryland Buchanan Communications Tel: 020 7466 5000
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.